glp 1 levels in obesity GLP-1 physiology informs the pharmacotherapy of Only one in 12 remain

Quality Counts: Not all CP or HA serums are created equal

Individual receptor sensitivity, baseline insulin resistance, genetic polymorphisms in GLP-1 and GIP receptors, and prior treatment duration all affect response

A large-scale observational study published in 2023 analyzed electronic health records of over 80,000 patients with obesity and found that those prescribed semaglutide had a 50-56% lower risk of alcohol use disorder compared to those on other obesity medications

certain allelic variants of several genes have been associated with an increased risk of essential hypertension, and almost all cases are known to be related to a familial history of hypertension (135)